• If you are wondering whether Organon stock offers solid value at today's price, it helps to start by lining up what the recent market action and the fundamentals are actually saying.
• The stock last closed at US$13.35, with returns of 0.2% over 7 days, 109.9% over 30 days, 84.4% year to date and 47.6% over 1 year, while the 3 year return sits at a 27.8% decline.
• Recent news around Organon has focused on its position within the pharmaceuticals space and how investors are reassessing the business after a period of weaker multi year returns. Coverage has highlighted the contrast between the sharp 30 day and 1 year performance figures and the 3 year return, which helps frame the current debate over whether the stock is now catching up or simply swinging in sentiment.
• Organon currently has a valuation score of 5 out of 6. The rest of this article will walk through traditional valuation approaches before coming to a more complete way to think about what that score really means for you.

Approach 1: Organon Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock might be worth by projecting future cash flows and discounting them back to today using a required rate of return.

For Organon, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $393.2 million. Analysts provide several years of explicit forecasts, and Simply Wall St then extrapolates further out. For example, projected Free Cash Flow for 2030 is $1,346 million, with intermediate years between 2026 and 2035 ranging from about $886.7 million to $1,661.2 million, all in $ and then discounted back to today's value.

Aggregating these discounted projections results in an estimated intrinsic value of $85.08 per share. Against the recent share price of $13.35, the model implies the stock trades at an 84.3% discount to this DCF estimate. This points to a wide gap between price and this particular estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Organon is undervalued by 84.3%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Organon Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you pay for the stock to the earnings it currently generates. It gives you a quick sense of how many dollars investors are paying for each dollar of earnings.

What counts as a "normal" P/E depends on factors like expected earnings growth and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while lower growth or higher risk typically supports a lower one.

Organon currently trades on a P/E of 14.25x. This sits below both the Pharmaceuticals industry average of 16.85x and the broader peer group average of 32.52x, suggesting the stock is priced more cautiously than many peers on this metric alone.

Simply Wall St’s Fair Ratio for Organon is 24.29x. This is a proprietary estimate of what P/E might be reasonable given the company’s earnings growth profile, profit margins, industry, market cap and risk factors. Because it adjusts for these company specific drivers, it can be more informative than a simple comparison with peers or the industry average.

With the current P/E of 14.25x sitting well below the Fair Ratio of 24.29x, Organon screens as undervalued on this earnings based approach.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Organon Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a simple way to attach your own story about Organon to the numbers by linking your view on its future revenue, earnings and margins to a financial forecast and then to a fair value that sits alongside the current price.

On Simply Wall St, Narratives live in the Community page and are already used by millions of investors, letting you see how different Organon stories translate into different fair value ranges, with some investors building a cautious narrative that supports a fair value near the lower US$5 target and others building a more optimistic narrative that supports a fair value around the higher US$12 target, so you can compare those views with the latest share price to decide whether Organon looks expensive or cheap on your assumptions.

Because Narratives update automatically when new information such as earnings releases, guidance or deal news comes through, your Organon story and the fair value that comes from it stay current, which helps you set clearer buy and sell thresholds instead of reacting only to short term share price moves.

Do you think there's more to the story for Organon? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.